本文關(guān)鍵詞：自擬益肝方配合西醫(yī)治療中晚期肝癌30例，由筆耕文化傳播整理發(fā)布。

中醫(yī)藥調(diào)節(jié)免疫微環(huán)境延緩肝癌復(fù)發(fā)轉(zhuǎn)移 首席醫(yī)學(xué)網(wǎng)      2014年04月22日 22:34:27 Tuesday  

作者：徐漢辰 宋海燕 楊金坤 季光    作者單位：上海中醫(yī)藥大學(xué)

【摘要】  肝癌是臨床上最常見的惡性腫瘤之一，手術(shù)、介入治療及近年開展的立體定向適形放射治療等均有良好的近期療效，，但都不能解決肝癌的復(fù)發(fā)和轉(zhuǎn)移問題。中醫(yī)藥已經(jīng)成為腫瘤輔助治療的主要手段，有效地改善了腫瘤患者的癥狀、延長(zhǎng)生存期、提高生活質(zhì)量、延緩復(fù)發(fā)和轉(zhuǎn)移。本文在簡(jiǎn)述肝癌的復(fù)發(fā)轉(zhuǎn)移與機(jī)體免疫功能的關(guān)系基礎(chǔ)上，總結(jié)近五年中醫(yī)藥調(diào)節(jié)免疫微環(huán)境延緩肝癌復(fù)發(fā)轉(zhuǎn)移的研究現(xiàn)狀。

【關(guān)鍵詞】  肝癌 免疫微環(huán)境 復(fù)發(fā)和轉(zhuǎn)移

【參考文獻(xiàn)】
  [1] 陸再英, 鐘南山. 內(nèi)科學(xué)[M]. 北京: 人民衛(wèi)生出版社, 2008: 457-462.
[2] 郭武華, 張吉翔. 肝癌綜合治療的現(xiàn)狀[J]. 世界華人消化雜志, 2008, 16: 2199-2203.
[3] 盧欣, 趙海濤, 毛一雷等. 肝細(xì)胞肝癌患者術(shù)后早期復(fù)發(fā)情況[J]. 中國(guó)醫(yī)學(xué)科學(xué)院學(xué)報(bào), 2008, 30(4): 415-419.
[4] 李朝軍. 劉嘉湘教授治療肝癌經(jīng)驗(yàn)[J]. 山西中醫(yī)雜志, 2009, 25(12): 9-10.
[5] 曹繼剛, 邱幸凡, 陳月雀等. 原發(fā)性肝癌的基本病機(jī)及治則探討[J]. 中醫(yī)藥學(xué)報(bào), 2008, 36(4): 28-29.
[6] 黃學(xué)武, 代興斌. 癌毒診治探討[J]. 新中醫(yī), 2008, 40: 6-7．
[7] 張金峰. 凌昌全癌毒學(xué)說運(yùn)用經(jīng)驗(yàn)[J]. 中醫(yī)雜志, 2008, 49(8): 693.
[8] 賈小強(qiáng), 黃乃健, 邱輝忠. 惡性腫留轉(zhuǎn)移的中醫(yī)病機(jī)研究恩路和策略[J]. 中醫(yī)藥臨床雜志, 2005, 17(1): 60-61.
[9] 顧健人, 楊勝利. 要用系統(tǒng)性疾病的觀念重新認(rèn)識(shí)癌癥[J]. 中華醫(yī)學(xué)雜志, 2005, 85: 505-507.
[10] 何維. 醫(yī)學(xué)免疫學(xué)[M]. 北京: 人民衛(wèi)生出版社, 2005: 348.
[11] D. Gabrilovich. Immunosuppressive strategies that are mediated by tumor cells. Annual Review of Immunology, 2007, 25: 267- 296.
[12] R. M. Hershberg, L. F. Mayer. Antigen processing and presenta- tion by intestinal epithelial cells-polarity and complexity. Immu- nology Today, 2000, 21(3): 123-128．
[13] 白廣德, 練祖平, 黃丁平等. 中西醫(yī)結(jié)合防治中晚期肝癌復(fù)發(fā)轉(zhuǎn)移的臨床研究[J]. 吉林中醫(yī)藥雜志, 2010, 30(8): 674- 675.
[14] 白廣德, 練祖平, 黃丁平等. 自擬益肝方配合西醫(yī)治療中晚期肝癌30例[J]. 陜西中醫(yī), 2008, 29(1): 16-19.
[15] 黃智芬, 黎漢忠, 施智嚴(yán). 健脾消積口服液結(jié)合西藥治療晚期肝癌40例的臨床觀察[J]. 中國(guó)中西醫(yī)結(jié)合雜志, 2003, 23(3): 192-194.
[16] V. Chew, C. Tow, M. Teo, et al. Inflammatory tumour microen- vironment is associated with superior survival in hepatocellular carcinoma patients. Journal of Hepatology, 2010, 52(3): 370- 379.
[17] L. Liu，J. Jia, G. Zeng, et al. Studies on immunoregulatory and anti-tumor activities of a polysaccharide from salvia miltiorrhiza Bunge. Carbohydrate Polymers, 2013, 92: 479-483.
[18] X.-N. Wang, X. Han, L.-N. Xu, et al. Enhancement of apoptosis of human hepatocellular carcinoma SMMC-7721 cells through synergy of berberine and evodiamine. Phytomedicine, 2008, 15(12): 1062-1068.
[19] G.-P. Sun，H. Wang, S.-P. Xu, et al. Anti-tumor effects of pae- onol in a HepA-hepatoma bearing mouse model via induction of tumor cell apoptosis and stimulation of IL-2 and TNF-α produc- tion. European Journal of Pharmacology, 2008, 584: 246-252.
[20] G. Dranoff, R. C. Mulligan. Gene transfer as cancer therapy. Ad- vances in Immunology, 1995, 58: 417-454.
[21] X. Ding, F. S. Zhu, S. G. Gao, et al. Purification, antitumour and immunomodulatory activity of water-extractable and alkali-ex- tractable polysaccha-rides from Solanum nigrum L. Food Chem- istry, 2012, 131(2): 677-684.
[22] H. Li, M. Sun, J. Xu, et al. Immunological response in H22 transplanted mice undergoing Aconitum coreanum polysaccha- ride treatment. International Journal of Biological Macromole- cules, 2013, 55: 295-300.
[23] X. H. Shen, N. Li, H. Li, et al. Increased prevalence of regula- tory T cells in the tumor microenvironment and its correlation with TNM stage of hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 2010, 136(11): 1745-1754.
[24] N. Kobayashi, N. Hiraoka, W. Yamagami, et al. FOXP3 + regu- latory T cells affect the development and progression of hepato- carcinogenesis. Clinical Cancer Research, 2007, 13(3): 902-911.
[25] Q. Li, J.-M. Bao, X.-L. Li, et al. Inhibiting effect of Astragalus polysaccharides on the functions of CD4+ CD25 high Treg cells in the tumor microenvironment of human hepatocellular carci- noma. Chinese Medical Journal 2012; 125(5): 786-793.
[26] Y. Lu, B.-Y. Zhang, Z.-X. Jia, et al. Hepatocellular carcinoma HepG2 cell apoptosisand caspase-8 and Bcl-2 expression in- duced by injectable seed extract of Coix lacryma-jobi. Hepatobiliary & Pancreatic Diseases International, 2011, 3(10): 303- 307.
[27] Z. X. Cheng, K. M. Wang, J. Wei, et al. Proteomic analysis of anti-tumor effects by tetrandrine treatment in HepG2 cells. Phy- tomedicine, 2010, 17(13): 1000-1005.
[28] D.-C. Chao, L.-J. Lin, S.-T. Kao, et al. Inhibitory effects of Zuo- Jin-Wan and it’s alkaloidal ingredients on activator protein 1, nuclear factor-κB, and cellular transformation in HepG2 cells. Fitoterapia, 2011, 82(4): 696-703.
[29] 湯釗酋. 現(xiàn)代腫瘤學(xué)[M]. 上海: 復(fù)旦大學(xué)出版社, 2011: 288．
[30] 劉彥平, 李積東. 枸杞多糖對(duì)小鼠NK細(xì)胞和白細(xì)胞活性的免疫調(diào)節(jié)作用[J]. 青海醫(yī)學(xué)院學(xué)報(bào), 2001, 22(1): l-2.
[31] 廉曉紅, 李德山, 竇玉琴等. 香茅草提取物的免疫調(diào)節(jié)作用與腫瘤抑制作用[J]. 沈陽藥科大學(xué)學(xué)報(bào), 2005, 22(4): 295- 297.
[32] 山廣志, 凌仕良. 應(yīng)用補(bǔ)陽還五湯維持治療肝癌術(shù)后患者35例[J]. 中國(guó)中醫(yī)藥科技, 2011, 18(2): 164-165.

  本文關(guān)鍵詞：自擬益肝方配合西醫(yī)治療中晚期肝癌30例，由筆耕文化傳播整理發(fā)布。